Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study - Concepedia

Concepedia

Publication | Open Access

Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study

DOI Full Paper Access

11

Citations

33

References

2023

Year

Merav Heshin‐Bekenstein, Amit Ziv, Nataša Toplak, Siman Lazauskas, Danielle Kadishevich, Efrat Ben-Nun Yaari, Adi Miller‐Barmak, Yonatan Butbul Aviel, Esther Saiag, Sara Pel,

Abstract

The safety profile of three doses of the BNT162b2 mRNA vaccine was excellent, with adequate humoral response and similar efficacy among patients and controls. These results support the recommendation for vaccinating adolescents with juvenile-onset AIIRDs against COVID-19.

References

	Year	Citations

Page 1